.jpeg)
FDA Accelerates Approval of Zongertinib: Precision Medicine Advancement for HER2-Mutated NSCLC
FDA Grants Accelerated Approval to Zongertinib(Hernexeos):Precision Breakthrough for HER2-Mutated Lung Cancer
On February 26,2026,the US FDA expedited approval of Zongertinib(brand name Hernexeos)for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer(NSCLC)harboring activating mutations in the tyrosine kinase domain(TKD)of HER2(ERBB2).This approval,grounded in compelling clinical efficacy data,ushers in a new era of targeted therapy for HER2-mutated lung cancer,addressing a critical unmet global medical need.
Key Highlights:
- Developer :Boehringer Ingelheim(Germany)
- Mechanism :Oral small-molecule kinase inhibitor targeting HER2-mutant oncogenic pathways
- Indication :HER2 TKD-mutated advanced non-squamous NSCLC(confirmed by FDA-authorized tests)
- Clinical Data :Notable 76%objective response rate(ORR)in pivotal trial,with>60%patients maintaining response for≥6 months
- Dosing :Bodyweight-adjusted regimen(120mg or 180mg once daily),with or without food
Safety&Risk Considerations:
Monitoring is required for hepatotoxicity,cardiac dysfunction,interstitial lung disease(ILD),and other potential risks.Contraindicated in pregnancy and lactation.
Landmark Significance:
-Fills therapeutic gap for HER2-mutated lung cancer
-Advances global precision oncology in lung cancer treatment
-Provides potent first-line option for treatment-naïve patients
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
